Home › NDC Lookup › RxCUI directory › RxCUI 259306

Alosetron 1 MG Oral Tablet — RxCUI 259306

RxNorm drug concept · Semantic clinical drug
RxCUI 259306 Semantic clinical drug · SCD ● Current RxNorm concept 15 FDA products 17 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI259306
Official nameAlosetron 1 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asalosetron 1 MG (as alosetron HCl 1.124 MG) Oral Tablet; alosetron HCl 1 MG Oral Tablet
FDA products mapped15
Package NDCs mapped17
Reported Medicaid activity (SDUD)566 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alosetron: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Alosetron is approved specifically for women with severe diarrhea-predominant IBS — that means IBS where diarrhea is the main problem, symptoms have been going on for at least 6 mo...
  • What exactly is alosetron used for — and can my husband take it too?
  • Constipation is the big one — it's actually the most common reason people stop taking alosetron. If you become constipated, stop the medication right away and call your prescriber...
  • What side effect should I watch out for most closely?
📖 Read our full Alosetron guide →

🕸️ Concept Web — How Alosetron 1 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Alosetron 1 MG Oral Tablet RxCUI 259306

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Alosetron 85248
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lotronex 261563
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alosetron Oral Tablet 379486
    • Alosetron Oral Product 1164913
    • Alosetron Pill 1164914
    • Alosetron Oral Tablet [Lotronex] 368200
    • Lotronex Oral Product 1180922
    • Lotronex Pill 1180923
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Alosetron 1 MG SCDC · 331499
  • Alosetron Oral Tablet SCDF · 379486
  • Alosetron Oral Product SCDG · 1164913
  • Alosetron Pill SCDG · 1164914

Brand-Name Concepts

  • Alosetron 1 MG Oral Tablet [Lotronex] SBD · 261362
  • Alosetron 1 MG [Lotronex] SBDC · 574581
  • Alosetron Oral Tablet [Lotronex] SBDF · 368200
  • Lotronex Oral Product SBDG · 1180922
  • Lotronex Pill SBDG · 1180923
  • Lotronex BN · 261563

📦 FDA Products & Package NDCs

15 products · 17 package NDCs
17 package NDCs map to RxCUI 259306 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
53746-0248-30 30 TABLET, FILM COATED in 1 BOTTLE (53746-248-30) Alosetron Hydrochloride Amneal Pharmaceuticals of New York LLC 2023-09-06
53746-0249-30 30 TABLET, FILM COATED in 1 BOTTLE (53746-249-30) Alosetron Hydrochloride Amneal Pharmaceuticals of New York LLC 2023-09-06
54766-0894-03 30 TABLET in 1 BOTTLE (54766-894-03) LOTRONEX Sebela Pharmaceuticals Inc. 2016-07-11
54766-0895-03 30 TABLET in 1 BOTTLE (54766-895-03) LOTRONEX Sebela Pharmaceuticals Inc. 2016-07-11
63629-2518-01 30 TABLET in 1 BOTTLE (63629-2518-1) Alosetron Bryant Ranch Prepack 2021-03-29
65162-0248-03 30 TABLET, FILM COATED in 1 BOTTLE (65162-248-03) Alosetron Hydrochloride Amneal Pharmaceuticals LLC 2017-01-02
65162-0248-50 500 TABLET, FILM COATED in 1 BOTTLE (65162-248-50) Alosetron Hydrochloride Amneal Pharmaceuticals LLC 2017-01-02
65162-0249-03 30 TABLET, FILM COATED in 1 BOTTLE (65162-249-03) Alosetron Hydrochloride Amneal Pharmaceuticals LLC 2017-01-02
65162-0249-50 500 TABLET, FILM COATED in 1 BOTTLE (65162-249-50) Alosetron Hydrochloride Amneal Pharmaceuticals LLC 2017-01-02
70756-0701-30 30 TABLET in 1 BOTTLE (70756-701-30) Alosetron Lifestar Pharma LLC 2020-09-14
70756-0702-30 30 TABLET in 1 BOTTLE (70756-702-30) Alosetron Lifestar Pharma LLC 2020-09-14
71930-0010-30 30 TABLET in 1 BOTTLE (71930-010-30) Alosetron Hydrochloride Eywa Pharma Inc 2019-02-01
71930-0011-30 30 TABLET in 1 BOTTLE (71930-011-30) Alosetron Hydrochloride Eywa Pharma Inc 2019-02-01
73190-0035-30 30 TABLET, FILM COATED in 1 BOTTLE (73190-035-30) Alosetron Hydrochloride AvKARE 2025-07-25
73190-0036-30 30 TABLET, FILM COATED in 1 BOTTLE (73190-036-30) Alosetron Hydrochloride AvKARE 2025-07-25
83107-0012-30 30 TABLET in 1 BOTTLE (83107-012-30) LOTRONEX Legacy Pharma USA Inc. 2026-01-01
83107-0013-30 30 TABLET in 1 BOTTLE (83107-013-30) LOTRONEX Legacy Pharma USA Inc. 2026-01-01
Observed labelers: Amneal Pharmaceuticals LLC (4) · Amneal Pharmaceuticals of New York LLC (2) · AvKARE (2) · Eywa Pharma Inc (2) · Legacy Pharma USA Inc. (2) · Lifestar Pharma LLC (2) · +2 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.